We have generated six high affinity monoclonal antibodies (MoAbs) to the human erythropoietin receptor (hEPO-R) polypeptide. All six MoAbs bind to the extracytoplasmic domain of the hEPO-R, and all immunoprecipitate j5S-labeled hEPO-R from metabolically labeled Ba/F3-hEPO-R cells. Four of the MoAbs neutralize the EPO-dependent growth of Ba/F3-hEPO-R cells, whereas two MoAbs are non-neutralizing. None of the MoAbs inhibit the EPO-dependent growth of Ba/F3 cells expressing the murine EPO-R (mEPO-R), even though the hEPO-R and mEPO-R share 82% amino acid identity. All six of the anti-EPO-R MoAbs bind to the cell surface human EPO-R but none bind to the cell surface murine EPO-R. Of the four neutralizing MoAbs, the one-half maximal inhibition occurs at MoAb concentrations ranging from 1 nmol/L to 50 nmol/L. These MoAbs RYTHROPOIETIN (EPO) is the primary regulator of E mammalian erythropoiesis. EPO mediates its activity by binding to a specific receptor (EPO-R) expressed on the surface of immature erythroblasts. Although murine' and humanzz3 EPO-R cDNAs have been isolated, there remain several unresolved questions regarding the quaternary structure of the EPO-R complex.
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The EPO-R exists in both high-and low-affinity states on the surface of FVA erythroblast^^.^ (erythroblasts infected with the anemia strain of the Friend Spleen Focus-Forming Virus) and transfected COS cells.' A structural explanation for these two affinity states has not been established. Furthermore, when radiolabeled EPO is crosslinked to the EPO-R, two major cross-linked complexes of approximately 140 Kd and 100 Kd are ~b s e r v e d .~ No correlation exists between the presence of the two crosslinked complexes and the two receptor affinities. For instance, murine erythroleukemia (MEL) cells demonstrate only the lower affinity receptor but yield both cross-linked complexes. It has been suggested that EPO induces the homodimerization of EPO-R,6 although homodimerization alone cannot account for the size of the cross-linked complexes.
The purpose of the current work was to generate specific, high-affinity MoAbs against the cloned human EPO-R to 0 I993 by The American Society qf Hematology.
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also compete with radiolabeled EPO for hEPO-R binding. The two non-neutralizing MoAbs fail to inhibit EPO-dependent growth or compete with EPO-binding, even at antibody concentrations as high as 500 nmol/L. The four neutralizing MoAbs, designated group 1, compete with each other for an epitope of the hEPO-R polypeptide required for EPO-binding. The two non-neutralizing MoAbs recognize discrete epitopes, and are designated group II and group Ill MoAbs. In conclusion, this is the first description of MoAbs specific for the hEPO-R. The MoAbs, which recognize three discrete epitopes, may be useful in characterizing the spectrum of cells that display the hEPO-R and in further defining the role of EPO in hematopoiesis. study EPO-R expression and structure. The six anti-EPO-R MoAbs generated recognize three discrete epitopes within the extracytoplasmic domain of the human EPO-R (hEPO-R) polypeptide. The MoAbs specifically bind to the hEPO-R polypeptide and do not bind to the murine polypeptide (mEPO-R), even though these proteins share 82% amino acid identity. Four of the MoAbs inhibit EPO binding and neutralize EPO-dependent growth. The two non-neutralizing MoAbs recognize discrete epitopes of hEPO-R, which do not contribute to the EPO binding site.
MATERIALS AND METHODS

Growth factors.
Highly purified recombinant human EPO was stored at -80°C ( I mg/mL). EPO was radiolabeled by the iodine monochloride technique to a specific activity of 1,000 cpm/fmol as previously described.' Radiolabeled EPO retained full biological activity. WEHI-conditioned media was used as a source of murine interleukin-3 (IL-3).'
Generation of MoAbs. Monoclonal anti-hEPO-R-antibodyproducing hybridoma cell lines were generated from two separate fusions using either mouse or hamster splenocytes. Balb/c mice were immunized with the purified secreted human EPO-R (shEPO-R) polypeptide.' This secreted hEPO-R was generated by insertion of a termination codon at the beginning of the transmembrane domain of the hEPO-R cDNA. Chinese hamsters (Cytogen Research and Development, West Roxbury, MA) were immunized with Chinese hamster ovary (CHO) cells expressing the cell surface human EPO-R. Animals were boosted with immunogen on the 4 days before fusion, splenocytes were harvested, and hybridization with p3x63Ag8.653 myeloma cells was performed as previously described.' Hybridoma supernatants were collected and assayed for the presence of antihuman EPO-R antibodies using standard enzyme-linked immunosorbent assay (ELISA) as the initial assay and either radioimmune precipitation or bioassay using FDCPE cell proliferation" as the secondary screening procedure. Twelve monoclonal anti-hEPO-R antibodies were derived, from which a panel of 6 MoAbs were selected for further study.
PuriJication of MoAbs. Cell culture or ascites fluid generated from each hybridoma cell line (approximately 100 mL) was clanfied by centrifugation at I,SOOg X I O minutes and filtered through a 0.45-mm filter. Ig-containing fractions were prepared on Protein A Sepharose (Pharmacia Fine Chemicals, Piscataway, NJ) as previously described.' The specificity of the anti-EPO-R MoAbs was on April 2, 2017. by guest www.bloodjournal.org From RU value is the average of six independent binding assays. As control, the MoAbs were prebound to secreted hEPO-R (1 pmol/L) before injection over the surface (hatched box). (B) Ba/F3 cells expressing the human EPO-R polypeptide were metabolically labeled with 35S-methionine and cysteine for 2 hours. labeled proteins were extracted with 1% Triton-X. and an equal amount (0.5 mL) of cell lysate was immunoprecipitated with the indicated MoAb. The upper arrow identifies the €PO-R polypeptide. The lower arrow identifies a proteolytic fragment of the EPO-R that was present in some immunoprecipitations and was confirmed by Western blot analysis using an antiserum against the amino terminal of the EPO-R polypeptide (not shown). 4 was hamster in origin (scc ahovc). All MoAhs were stored as I mg/mL stocks in phosphate-huffcred saline (PRS). As controls. a ncutralizinganti-EPO MoAh(5.5.I 1)9and a ncutralizinganti-murinc IL-3 MoAh (Genzymc Corp. Boston. MA) were uscd.
,~lssriy oluti/i-/</'O-R .\lo:lh liItiditi,r. Standard conditions for assaying MoAh hinding with the RlAcore apparatus (Pharmacia) wcrc uscd." The Riacore system allows a measure of antihody-antigen interactions in real time. Thc system uscs surface plasmon resonance to detect changes in optical properties at the surface ofa thin gold film. Initially. an antigen (sEPO-R) iscovalcntlycoupled to the surface. Next, an antihody is introduced in a flow pasing over the surface. Resonance (RU value) is measured. which is directly proportional to the mas of the new protein (antihody) hound to the surface. No laheling of the ligands is therefore required.
Specifically. for thcsc studies purified sccreted EPO-R (2.8 ms/ mL in PRS) (approximately 100 pmol/L) was immohilized to a carboxylated dextran matrix. Unreacted groups were blocked hy the injection of3OpLofethanolaminc. pH = 8.5. followed hy IS pL of SO nmol/L NaOH to remove noncovalcntly hound peptide.
MoAh (IO0 nmol/L) was allowed to interact with the sensor surface. Runs were performed at 25°C at a flow rate of 3 pL/min. The surface was regenerated hy injecting a SO-nmol/L HCL solution over 2 minutes (6 pl. injection).
Ra/F3 cells. a murine IL-3-depndcnt line." were grown as previously dcscrihed.' Ra/F3 cells were electroporated with either PXM-mEPO-R' or PXM-hEPO-R' as previously dc-
scrihed.'
/t,itnrinriprc~cipircrriorr (?/. ruditilrrhc~lc~/ EPO-r, Immunoprccipitation of radiolaheled EPO-R was performed as previously dcscribed' with a few modifications. Ra/F3 hEPO-R cells were metahelically laheled with "S-methionine and '5S-cysteine ("S-Expms: New England Nuclear. Boston. MA). Cell lysates were preparcd. and laheled proteins from a n equal volume of cell lysate were immunoprecipitated with IO pgof the indicated MoAh. Proteins were eluted in gel sample huffer and run on IOr;. polyacwlamidc/sodium dodecyl sulfate gels in the prcscnce of IO mmol/L dithiothreitol.
Ra/F3-hEPO-R or Ra/ F3-mEPO-R were grown in EPO media as previously dcscrihed.' To assay factor-stimulated growth. cells were washed twice in Plain media (RPMI + IO'.; fetal calfscrum with no supplemental gromqh factor)and resuspendcd in Plain media. Cclls(S x 104cclls/100pL) were added to multiplc wells o f a 96-well plate. Supplemental EPO. IL-3. o r MoAh was added as indicated and growth was measured after 48 hours hy the dimcthylthiazol diphenyl-tetrazolium bromide (MTT) reduction assay. ' Rriditiluhc~lid 
RESULTS
Initially, the specificity of the MoAbs against hEPO-R was assayed (Fig 1) . For these experiments the secreted hEPO-R polypeptide (amino acids 1-223) was covalently coupled to a solid matrix, and binding of the anti-EPO-R MoAbs was tested directly using the BIAcore system (Pharmacia Biosensor AB, Uppsala, Sweden). This system has previously been used to assay association rates of MoAb/antigen interactions." Binding of MoAb to immobilized EPO-R peptide is measured in RU, which is proportional to the refractive index increment and therefore to the mass of protein bound to the surface." Figure 1A shows that all six MoAbs specifically bind to secreted hEPO-R (RU values ranging from 1540 to 2 12 I), whereas a mock MoAb shows no specific binding. When the MoAbs were prebound in solution with an excess of secreted hEPO-R, binding to the solid matrix was inhibited (Fig lA,  hatched boxes) .
The specificity of the MoAbs was further tested by immunoprecipitation of the full-length 3SS-labeled human EPO-R, solubilized from metabolically labeled Ba/F3-hEPO-R cells (Fig 1 B) . The MoAbs immunoprecipitated a single band of 66 Kd (Fig I B, upper arrow) , consistent with the size of the human EPO-R described MoAbs no. 1 and 5 demonstrate the most efficient immunoprecipitation of human EPO-R; MoAbs no. 2, 3, 4, and 6 only weakly immunoprecipitate the full-length polypeptide. Also, all six MoAbs recognize the full-length hEPO-R polypeptide by Western blot analysis (data not shown).
Neutralization of EPO-dependent growth by the anti-EPO-R MoAbs. To assay the bioactivity of the anti-EPO-R MoAbs, we generated EPO-dependent Ba/F3 subclones (Fig 2) . Ba/F3 cells, which are murine IL-3 dependent," were stably transfected with either the human EPO-R or the murine EPO-R cDNAs and individual subclones were isolated by limiting dilution. Ba/F3-hEPO-R and Ba/F3-mEPO-R cells had similar EPO-dependent growth (one-half maximal growth at 50 mU/mL, or 5 pmol/L EPO). These cell lines also had similar IL-3-dependent growth (one-half maximal growth in 5% WEHI-conditioned media) (data not shown). We tested the ability of the anti-EPO-R MoAbs, at a single concentration of MoAb (100 nmol/L), to inhibit growth of Ba/F3-hEPO-R cells, growing in EPO or IL-3 ( Fig 2B) . MoAbs no. I , 2, 3, and 6 all inhibited EPO-dependent growth, whereas MoAbs no. 4 and 5 only slightly inhibited EPO-dependent growth. None of the anti-EPO-R MoAbs inhibited IL-3-dependent growth, confirming that the MoAbs specifically bind to the human EPO-R but not to Specificity of anti-EPO-R MoAbs. For personal use only. on April 2, 2017. by guest www.bloodjournal.org From (Fig 2C) . The MoAbs therefore specifically interact with the human and not the murine EPO-R polypeptide, even though these proteins have 82% amino acid id en tit^.^,^ To further assess the direct interaction of the anti-EPO-R MoAbs with the cell surface hEPO-R, we used a binding competition assay (Fig 3) . Ba/F3-hEPO-R cells were incubated with a single concentration of 1Z51-EP0 (200 pmol/L) either in the presence or absence of excess cold EPO, and with the various MoAbs. A subpopulation of MoAbs (MoAbs no. 1, 2,3, and 6 ) inhibited lZ5I-EPO binding, whereas MoAbs no. 4 and 5 did not. The inhibition of EPO binding by the MoAbs therefore correlates well with their ability to neutralize the bioactivity of EPO (Fig 2B) .
Because MoAb no. 5 failed to compete with radiolabeled EPO binding, we next tested its ability to bind directly to the cell surface hEPO-R using FACS analysis (Fig 4) . For this analysis we compared MoAb no. 1 (neutralizing) and MoAb no. 5 (non-neutralizing) because these MoAbs are both murine and both of IgGl subclass. MoAbs no. 1 and 5 had comparable binding to the Ba/F3-hEPO-R cells. Consistent EPO-R binding (Fig 4, A v B) but not with MoAb no. 5 (Fig   4, c v D) , su%esting that these MoAbs recognize different epitopes of hEPO-R.
By FACS analysis (data not shown), all six anti-EPO-R MoAbs bind to the cell surface human EPO-R polypeptide but none bind to the murine EPO-R polypeptide. This result further confirms the specificity of the MoAbs for the human EPO-R and accounts for their failure to neutralize EPO-dependent growth of Ba/F3-mEPO-R cells (Fig 2C) .
Dose-dependent inhibition of EPO-dependent growth of Bu/F3-HEPO-R cells by anti-EPO-R MoAbs. We investi-
Binding of MoAbs to the cell surface EPO-R. gated the effects of various concentrations of the anti-EPO-R MoAbs on EPO-dependent or IL-3-dependent cell growth (Fig 5) . MoAbs no. 1, 2, 3, and 6 showed dose-dependent inhibition of EPO-mediated growth of Ba/F3-hEPO-R cells, but had no effect on IL-3-mediated growth (Fig 5A, B Fig 5D and E) showed little or no specific inhibition of EPO-mediated growth or IL-3-mediated growth, even at MoAb concentrations as high as 500 nmol/L.
F l u o r e s c e n c e
The anti-EPO-R MoAbs recognize different epitopes of the EPO-R polypeptide. The specific epitopes of the hEPO-R polypeptide, recognized by the six MoAbs, were further evaluated in an epitope exclusion experiment (Fig 6) using the BIAcore instrument. Initially, secreted hEPO-R was covalently coupled to a solid matrix (chip). Secondly, the chip was saturated with a high concentration ( 100 nmol/ L) of MoAb no. 1. The ability of a second antibody (10 nmol/L) to bind to the receptor was then tested. As expected, prebound MoAb no. 1 efficiently blocked the binding of additional MoAb no. 1 (RU = 265). Likewise, each MoAb inhibited further binding of self (Fig 6, shaded diagonal) . On the basis of these experiments MoAbs no. I , 2, 3, and 6 compete for the same epitope of human EPO-R polypeptide and, by definition, belong to group I. MoAb no. 4 and 5, the non-neutralizing MoAbs, each bind to discrete non-overlapping epitopes of EPO-R and thereby comprise group I1 and group 111 MoAbs, respectively.
DISCUSSION
By immunizing mice with a secreted version of the extracytoplasmic region of the hEPO-R or by immunizing hamsters with CHO cells expressing cell surface hEPO-R, we have raised six MoAbs that bind specifically to the cell surface human EPO-R complex. The monoclonals are highly specific for the human EPO-R and do not interact with the mEPO-R, even though the hEPO-R and mEPO-R have 82% amino acid identity.'~~ Four of the MoAbs block EPO binding to the human EPO-R and, accordingly, inhibit the EPO-induced proliferative response.
In contrast, the anti-hEPO-R MoAbs neither blocked IL-3-driven proliferation of the Ba/F3 cells nor bound to the murine IL-3R (AIC2A or AIC2B).I3,l4 This observation suggests that the hEPO-R in Ba/F3-hEPO-R cells functions independently of the AIC2A and AIC2B IL-3R subunits expressed in these cells. In accord with this data, MoAbs to AIC2A and AIC2B do not inhibit EPO-induced proliferat i~n . '~? '~ Also, previous studies have demonstrated that the EPO-R polypeptide can confer EPO-dependent growth on CTLL cells, which lack both AIC2A and AIC2B.I6
On the basis of epitope exclusion studies, the six anti-EPO-R MoAbs were divided into three groups. Group I MoAbs compete with radioiodinated EPO binding and neutralize EPO-dependent growth of Ba/F3-hEPO-R cells. In contrast, group I1 and group 111 MoAbs recognize discrete epitopes of the extracytoplasmic region of hEPO-R but do not inhibit EPO-binding.
The anti-EPO-R MoAbs should be useful in studying the EPO-binding pocket of the native EPO-R complex. The EPO-R is a member of the cytokine receptor superfamily." Although its crystal structure is not known, it is probably similar to the crystal structure ofthe growth hormone receptor," another member of this superfamily. The growth hormone receptor: ( 1) contains two distinct extracytoplasmic domains, both of which contribute residues to the growth hormone binding site; and (2) undergoes homodimerization after monomeric ligand binding. By analogy, we would predict that our group I antibodies recognize an epitope formed by two domains of the EPO-R polypeptide extracytoplasmic region.
By several criteria, it is likely that the group I MoAbs bind directly to the EPO-binding site of the EPO-R polypeptide. First, group I MoAbs specifically inhibit EPO-binding by the receptor (Fig 3) . Conversely, EPO inhibits the binding of MoAb no. 1 to the receptor (Fig 4) . It is possible that EPO has multiple contact points on the EPO-R, only one of which is blocked by the antibody. Alternatively, although less likely, EPO binding could indirectly block MoAb bindFor personal use only. on April 2, 2017. by guest www.bloodjournal.org From ing by steric inhibition or by inducing a conformational change in the EPO-R that alters epitope recognition.
The cloned hEPO-R polypeptide may be only one component of the native EPO-R complex.'' Because group I MoAbs block EPO-binding, we can conclude that the hEPO-R polypeptide itself binds directly to EPO. Consistent with this observation, Harris et a12' have recently demonstrated that hEPO-R fusion proteins bind directly to EPO. Also, a polyclonal antiserum raised against the extracytoplasmic domain of the human EPO-R polypeptide blocks EPO binding.*' We cannot rule out the existence of other EPO-R subunits that contribute to the EPO-binding pocket.
These MoAbs may be useful for future studies. First, they will be useful in signal transduction studies. Like EPO, they may induce EPO-R-associated tyrosine kinase activity,21 EPO-R phosphorylation,22 and EPO-R homodimerization.6 Secondly, they may be useful in analyzing and isolating early erythroblasts in bone marrow samples, as well as in distinguishing erythroleukemia (AML, M6 morphology), which comprises approximately 1% to 3% of human acute myeloblastic leukemia. Finally, because the MoAbs specifically recognize the hEPO-R and not the mEPO-R, chimeric receptors containing regions of the human and murine polypeptides should help delineate the specific epitopes recognized.
